Project Grant K08CA304491
Award Date 8/17/26
Completion Date 7/31/30
Dollars Obligated $281K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
- The National Cancer Institute awarded the Beckman Research Institute of the City of Hope $162,000 on August 11, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and pilot a self-directed e-learning delivery model for clinical cancer genomics education. The recipient will convert selected core recorded didactic modules from its established Intensive Course in Clinical Cancer Genomics into a self-directed e-learning course bundle using theoretically grounded...
- The National Cancer Institute of the Department of Health and Human Services awarded the Beckman Research Institute of the City of Hope $733,864 on June 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to identify and characterize stimulatory immune checkpoints regulating macrophage-mediated programmed cell removal in tumor immunosurveillance. The research uses high-throughput CRISPR-based screening to investigate how a novel stimulatory innate immune checkpoint interacts with...
- The National Cancer Institute awarded $269,597 to the Beckman Research Institute of The City of Hope on August 10, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and deliver clinical trials nursing education. The recipient will create a curriculum to train oncology clinical trials nurses in quality care for patients enrolled in cancer treatment trials, deliver the curriculum through five national in-person courses and virtual offerings to competitively selected...
- The National Cancer Institute awarded the University of California, Los Angeles $737,181 on July 22, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a multisite randomized controlled trial designed to improve functional recovery and mitigate frailty after hematopoietic cell transplantation in older adults over age 60. The trial, titled SEN-ENERGY, addresses a significant gap in evidence-based care for a growing population. More than 45% of hematopoietic cell...
- The National Cancer Institute awarded Duke University $433,658 under the Cancer Treatment Research program on September 1, 2026, to investigate how toll-like receptor 4 activity in mesenchymal stromal cells contributes to skeletal muscle decline and fibrosis induced by cancer treatment. The research addresses accelerated frailty in pediatric cancer survivors who receive fractionated X-ray irradiation. The award funds a murine model study examining radiation-induced muscle weakness, myofiber...
- The Defense Health Agency awarded Beckman Research Institute of the City of Hope $1,099,996 on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to develop LRRC15-targeted CAR T cell therapy for osteosarcoma. The award funds three years of research performance through May 31, 2029, conducted at Beckman's Irwindale, California facility. This project grant is one of multiple R&D assistance sub-programs within the Defense Health Program focused on...
- The National Institutes of Health National Cancer Institute awarded Beckman Research Institute of the City of Hope $2,486,215 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing R01CA313241) to conduct mutational epidemiology research on childhood acute lymphoblastic leukemia in California. The research combines tumor mutation pattern analysis with epidemiological methods to identify environmental causes of childhood ALL. The project leverages the...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $252,023 on September 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to adapt an evidence-based goals-of-care communication intervention for adolescent and young adult cancer patients (ages 15–39). The project addresses poor end-of-life outcomes in this population, including high rates of futile aggressive care interventions in the final month of life and low hospice enrollment. Current...
- The Defense Health Agency awarded $1.399 million to Beckman Research Institute of the City of Hope on August 31, 2026, under the Military Medical Research and Development program (CFDA 12.420) to support research targeting aberrant end-joining repair for improving treatment of mixed phenotype acute leukemia. The award runs through July 31, 2029, with performance at Beckman's Irwindale, California facility. This project grant supports basic and applied biomedical research to transform health care...
- The National Cancer Institute awarded Beckman Research Institute of the City of Hope $736,457 under the Cancer Treatment Research program (CFDA 93.395) on June 26, 2026, to develop small-molecule inhibitors targeting protein-protein interactions within the ERKS axis (comprising EphrinB, RGS3, KIF20A, and SEPT7) as a differentiation therapy for malignant brain tumors, particularly glioblastomas. The research employs a protein-protein interaction-based high-throughput screening assay to isolate...